Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis
Author:
Affiliation:
1. Epidemiology, Biostatistics and Prevention Institute, University of Z�rich, Z�rich, Switzerland. TBRieder@tbrieder.org
2. Mycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
Publisher
International Union Against Tuberculosis and Lung Disease
Subject
Infectious Diseases,Pulmonary and Respiratory Medicine
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Synergistic combination of antimicrobial peptide and isoniazid as inhalable dry powder formulation against multi-drug resistant tuberculosis;International Journal of Pharmaceutics;2024-04
2. Mechanisms of Mycobacterium tuberculosis Drug Resistance;Molecular Genetics, Microbiology and Virology;2024-03
3. Mycobacterium tuberculosis drugs resistance mechanisms;Molecular Genetics Microbiology and Virology (Russian version);2024
4. Isoniazid resistance-conferring mutations are associated with highly variable phenotypic resistance;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2023-12
5. High rate of adverse drug reactions with a novel tuberculosis re-treatment regimen combining triple doses of both isoniazid and rifampicin;International Journal of Infectious Diseases;2023-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3